<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="683618" id="root" date="1997-06-24" xml:lang="en">
<title>SWEDEN: Astra says gets FDA nod for Pulmicort Turbuhaler.</title>
<headline>Astra says gets FDA nod for Pulmicort Turbuhaler.</headline>
<dateline>STOCKHOLM 1997-06-24</dateline>
<text>
<p>Swedish drugs company Astra said on Tuesday that the U.S. Food and Drug Administration (FDA) had approved its anti-asthma treatment, the Pulmicort Turbuhaler.</p>
<p>Astra said in a statement that the FDA had approved the treatment for long-term use by adults and for children aged six and over.</p>
<p>It would be introduced in the U.S. in the autumn of this year.  </p>
<p>The clinical name for the drug is budesonide inhalation powder.</p>
<p>&quot;Pulmicort Turbuhaler is the first corticosteroid dry powder inhaler for asthma to be approved in the United States,&quot; Astra said in a statement.</p>
<p>The drug company's patented Turbuhaler delivers the substance through an inhaler without the use of propellant gases like chlorofluorocarbons (CFCs), Astra said.</p>
<p>Clinical tests show the device administers the drug more effectively than traditional aerosol inhalers, it said.</p>
<p>Astra CEO Hakan Mogren said the approval was a milestone for the company.</p>
<p>&quot;Pulmicort has grown to become a leading anti-asthma drug in Europe, Australia and Canada. Our intention is to make Pulmicort a leading anti-asthma medication in the United States as well,&quot; Mogren said in the statement.</p>
<p>Pulmicort Turbuhaler is now approved in 64 countries. Sales in 1996 increased by 17 percent to 4.73 billion crowns, Astra said.</p>
<p>Astra shares have risen steadily in recent days amid market speculation that FDA approval was imminent.</p>
<p>Astra shares closed 1.5 crowns higher at 141 crowns on Tuesday.</p>
<p>-- Abigail Schmelz, Stockholm newsroom +46-8-700-1003</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="SWED">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-24"/>
  </code>
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-24"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-24"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C13">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-24"/>
  </code>
  <code code="C22">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-24"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-06-24"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-06-24"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-06-24"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="STOCKHOLM"/>
<dc element="dc.creator.location.country.name" value="SWEDEN"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
